Transforming Clinical Research: myTomorrows’ GenAI Solution for Universal Trial Access

By Danny den Hamer, Product Manager at myTomorrows 

Clinical research play a crucial role in the development of new therapies and advancing public health. Recruiting patients for clinical trials, however, remains one of the most significant challenges faced by trial sites and sponsors, threatening the efficiency, inclusivity, and financial sustainability of the clinical research process. A staggering 80% of clinical trials are delayed¹ or even closed due to recruitment issues, underscoring the persistent nature of the problem. Healthcare Professionals (HCPs), on the other hand, seeking access to pre-approval options for their patients grapple with a rapidly growing landscape of clinical trials, each with increasingly complex eligibility criteria. With over 500,000 trials registered globally² and more than 8,000 drugs in the global clinical development phase to date³, navigating this process whilst staying informed on the latest research can be daunting.

The Solution: myTomorrows’ Next-Gen AI Powered Platform

We’re proud to unveil our next generation AI-powered platform — a transformative tool designed to streamline clinical trial search and patient eligibility pre-screening with precision. In this evolution of our platform we introduce advanced automation of the eligibility checking process, delivering significantly greater time-saving efficiencies than before.

At its core, our unique AI pre-screening technology is now able to deliver on two game-changing breakthroughs:

• Unmatched accuracy: In benchmark tests on Harvard’s n2c2 Partners HealthCare (i2b2) NLP datasets, myTomorrows’ AI tool achieved a Macro F1 of 0.91, an improvement over Stanford’s previous best of 0.81. It also delivered a Micro F1 of 0.91, nearly matching Stanford’s record of 0.93. These results show that myTomorrows’ AI tool strikes the right balance – it effectively captures both frequent and rare conditions in eligibility criteria, helping to ensure that less obvious medical details are not missed when matching patients to clinical trials.

• Superhuman precision: In performance testing against a user test group of individuals with medical background, across 9 diseases areas and 490 trials, myTomorrows’ AI tool achieved 98% accuracy in checking patient clinical trial eligibility. It outperforms manual eligibility review by the user test group, who on average are 93% accurate at classifying trial eligibility in the test.

For more information about both the n2c2 benchmark and internal performance testing, you can contact us at beta@mytomorrows.com.

Empowering Healthcare Professionals

Today marks a step forward in our vision to revolutionize access to treatments for everyone by harnessing the power of technology. The high accuracy of our AI tool enables us to automate the eligibility checking process, reducing healthcare professionals’ workload by up to 90%⁴ and cutting pre-screening time from hours to minutes .

Our AI-powered platform transforms trial matching by analyzing patient medical data against each study’s inclusion and exclusion criteria, automatically categorizing trials as eligible or ineligible. It provides a clear rationale for its classification, allowing HCPs to confidently verify and select the most relevant trials from the list of results, including trials for precision medicine, solid tumors and targeted therapies. Unlike standard questionnaires, our criterium-level evaluation screens unique patient data such as histology, biomarkers, lab values etc., ensuring that every potential patient matches detailed eligibility requirements before referral.

The ‘latest clinical data’ feature provides further information about the mechanism of action and known efficacy and safety profile of the investigated intervention, supporting HCPs in making an informed decision when selecting a trial. Leveraging proprietary algorithms, our platform sources trial information from registries like ClinicalTrials.gov, EudraCT, and ISRCTN, providing a comprehensive global view of trials in one place. By unlocking visibility of trials that may have been overlooked, we empower HCP efforts in exploring all treatment options for their patients, and improving access to emerging therapies when standard of care falls short.

On our ISO-27001 certified, GDPR, HIPAA and SOC II compliant platform, HCPs can also search, pre-screen and directly refer patients to sites—all within a single, secure system. Sites receiving these highly pre-qualified referrals can also easily manage, track or request patient information directly from referring HCPs on the platform.

With these capabilities, we tackle some of the major pain points HCPs face when navigating access to clinical trials:

• time-consuming trial search and matching,
• limited awareness of available trials,
• cumbersome error-prone pre-screening due to trial eligibility criteria and complex patient cases,
• communication barriers with trial sites and privacy concerns.

Our AI tool does not replace integral physician care but instead provides opportunity for an optimal partnership model with HCPs. This approach enables HCPs to efficiently access the most relevant treatment options for their patients and allow them to confidently make informed decisions every step of the way. By eliminating the burden of manual, time-consuming tasks, HCPs can focus on what truly matters — delivering the best possible care for their patients.

Enabling Smarter Recruitment

myTomorrows’ next-generation technology and comprehensive data insights streamline trial matching for HCPs and patients while enhancing protocol development cycles—accelerating the clinical research process. With high-precision matching and automated pre-screening, research teams can reduce screen failures, streamline enrollment, and lower operational costs. Our AI-driven platform enables trial sites to pre-screen patients from their own site and incoming referrals from external network, maximizing every recruitment opportunity. By improving efficiency and enrollment rates, we minimize costly protocol amendments for sites and sponsors. More importantly, we free up valuable time and resources for research teams to focus on patient care and core research activities.

Accelerate your recruitment today 

What’s Next

At myTomorrows, our journey doesn’t stop here. We’re committed to serving and connecting all stakeholders across the care continuum and pre-approval journey. The next opportunity is to build for scale. For enterprises and teams navigating clinical trials at scale, we’re taking efficiency to the next level.

Coming soon, organizations will be able to seamlessly integrate our pioneering pre-screening AI tool and other platform functionalities into their existing technology stack. Built for screening at scale, the integration with existing Electronic Health Records (EHRs) and industry workflows will enable pre-screening of high-volume patient populations in real-time with unmatched precision. By analyzing vast structured and unstructured EHR data such as physicians’ notes, pathology reports, and genomics data, our AI tool enables earlier patient identification, ensuring more qualified patients gain timely access to trials.  With this advancement, we aim to unlock immense efficiency gains and empower teams to accelerate the overall clinical research process and bring emerging treatments to patients faster.

The future of clinical trial recruitment is here